103 related articles for article (PubMed ID: 21456625)
1. Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4).
Day JP; Lindsay B; Riddell T; Jiang Z; Allcock RW; Abraham A; Sookup S; Christian F; Bogum J; Martin EK; Rae RL; Anthony D; Rosair GM; Houslay DM; Huston E; Baillie GS; Klussmann E; Houslay MD; Adams DR
J Med Chem; 2011 May; 54(9):3331-47. PubMed ID: 21456625
[TBL] [Abstract][Full Text] [Related]
2. p62 (SQSTM1) and cyclic AMP phosphodiesterase-4A4 (PDE4A4) locate to a novel, reversible protein aggregate with links to autophagy and proteasome degradation pathways.
Christian F; Anthony DF; Vadrevu S; Riddell T; Day JP; McLeod R; Adams DR; Baillie GS; Houslay MD
Cell Signal; 2010 Oct; 22(10):1576-96. PubMed ID: 20600853
[TBL] [Abstract][Full Text] [Related]
3. Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process.
Terry R; Cheung YF; Praestegaard M; Baillie GS; Huston E; Gall I; Adams DR; Houslay MD
Cell Signal; 2003 Oct; 15(10):955-71. PubMed ID: 12873709
[TBL] [Abstract][Full Text] [Related]
4. p62 (SQSTM1) forms part of a novel, reversible aggregate containing a specific conformer of the cAMP degrading phosphodiesterase, PDE4A4.
Houslay MD; Christian F
Autophagy; 2010 Nov; 6(8):1198-200. PubMed ID: 20864809
[TBL] [Abstract][Full Text] [Related]
5. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
[TBL] [Abstract][Full Text] [Related]
6. Engineered stabilization and structural analysis of the autoinhibited conformation of PDE4.
Cedervall P; Aulabaugh A; Geoghegan KF; McLellan TJ; Pandit J
Proc Natl Acad Sci U S A; 2015 Mar; 112(12):E1414-22. PubMed ID: 25775568
[TBL] [Abstract][Full Text] [Related]
7. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).
Cameron RT; Coleman RG; Day JP; Yalla KC; Houslay MD; Adams DR; Shoichet BK; Baillie GS
Biochem Pharmacol; 2013 May; 85(9):1297-305. PubMed ID: 23473803
[TBL] [Abstract][Full Text] [Related]
8. Identification of a PDE4-Specific Pocket for the Design of Selective Inhibitors.
Feng X; Wang H; Ye M; Xu XT; Xu Y; Yang W; Zhang HT; Song G; Ke H
Biochemistry; 2018 Jul; 57(30):4518-4525. PubMed ID: 29975048
[TBL] [Abstract][Full Text] [Related]
9. Molecular Bases of PDE4D Inhibition by Memory-Enhancing GEBR Library Compounds.
Prosdocimi T; Mollica L; Donini S; Semrau MS; Lucarelli AP; Aiolfi E; Cavalli A; Storici P; Alfei S; Brullo C; Bruno O; Parisini E
Biochemistry; 2018 May; 57(19):2876-2888. PubMed ID: 29652483
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of PDE IV inhibitors. First asymmetric synthesis of two of GlaxoSmithKline's highly potent Rolipram analogues.
Zhmurov PA; Sukhorukov AY; Chupakhin VI; Khomutova YV; Ioffe SL; Tartakovsky VA
Org Biomol Chem; 2013 Dec; 11(46):8082-91. PubMed ID: 24169629
[TBL] [Abstract][Full Text] [Related]
11. Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2.
Nankervis JL; Feil SC; Hancock NC; Zheng Z; Ng HL; Morton CJ; Holien JK; Ho PW; Frazzetto MM; Jennings IG; Manallack DT; Martin TJ; Thompson PE; Parker MW
Bioorg Med Chem Lett; 2011 Dec; 21(23):7089-93. PubMed ID: 22030030
[TBL] [Abstract][Full Text] [Related]
12. Small molecule allosteric modulators of phosphodiesterase 4.
Gurney ME; Burgin AB; Magnusson OT; Stewart LJ
Handb Exp Pharmacol; 2011; (204):167-92. PubMed ID: 21695640
[TBL] [Abstract][Full Text] [Related]
13. Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis.
Felding J; Sørensen MD; Poulsen TD; Larsen J; Andersson C; Refer P; Engell K; Ladefoged LG; Thormann T; Vinggaard AM; Hegardt P; Søhoel A; Nielsen SF
J Med Chem; 2014 Jul; 57(14):5893-903. PubMed ID: 24984230
[TBL] [Abstract][Full Text] [Related]
14. Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors.
Kato Y; Kawasaki M; Nigo T; Nakamura S; Fusano A; Teranishi Y; Ito MN; Sumiyoshi T
Bioorg Med Chem; 2013 Sep; 21(18):5851-4. PubMed ID: 23910988
[TBL] [Abstract][Full Text] [Related]
15. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors.
Wang H; Peng MS; Chen Y; Geng J; Robinson H; Houslay MD; Cai J; Ke H
Biochem J; 2007 Dec; 408(2):193-201. PubMed ID: 17727341
[TBL] [Abstract][Full Text] [Related]
16. Construction of a six-membered fused N-heterocyclic ring via a new 3-component reaction: synthesis of (pyrazolo)pyrimidines/pyridines.
Kumar PM; Kumar KS; Mohakhud PK; Mukkanti K; Kapavarapu R; Parsa KV; Pal M
Chem Commun (Camb); 2012 Jan; 48(3):431-3. PubMed ID: 22075973
[TBL] [Abstract][Full Text] [Related]
17. Diastereoselective synthesis and profiling of bicyclic imidazolidinone derivatives bearing a difluoromethylated catechol unit as potent phosphodiesterase 4 inhibitors.
Dorokhov VS; Golovanov IS; Tartakovsky VA; Sukhorukov AY; Ioffe SL
Org Biomol Chem; 2018 Oct; 16(38):6900-6908. PubMed ID: 30024008
[TBL] [Abstract][Full Text] [Related]
18. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center.
Freund YR; Akama T; Alley MR; Antunes J; Dong C; Jarnagin K; Kimura R; Nieman JA; Maples KR; Plattner JJ; Rock F; Sharma R; Singh R; Sanders V; Zhou Y
FEBS Lett; 2012 Sep; 586(19):3410-4. PubMed ID: 22841723
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents.
Barberot C; Moniot A; Allart-Simon I; Malleret L; Yegorova T; Laronze-Cochard M; Bentaher A; Médebielle M; Bouillon JP; Hénon E; Sapi J; Velard F; Gérard S
Eur J Med Chem; 2018 Feb; 146():139-146. PubMed ID: 29407945
[TBL] [Abstract][Full Text] [Related]
20. Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains.
Bolger GB; Dunlop AJ; Meng D; Day JP; Klussmann E; Baillie GS; Adams DR; Houslay MD
Cell Signal; 2015 Apr; 27(4):756-69. PubMed ID: 25546709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
